Type 1 Diabetes Management: Insulin, CGM & Closed-Loop Systems

An Autoimmune Disease, Not a Lifestyle Disease

Type 1 diabetes (T1D) destroys the pancreatic beta cells that produce insulin through an autoimmune process, leaving the body completely unable to regulate blood glucose without external insulin. The C-peptide test makes this distinction concrete: C-peptide, a byproduct of endogenous insulin synthesis, is absent or negligible in T1D but present in type 2 diabetes. This single biomarker separates a disease of immune failure from one of metabolic resistance — and it determines treatment forever. Approximately 8.4 million people worldwide live with T1D, according to the International Diabetes Federation's 2021 Atlas, and that number is rising roughly 2–3% per year in high-income countries for reasons researchers have not fully explained.

Insulin Delivery: Two Primary Strategies

Without functional beta cells, people with T1D must replace insulin externally. Two major strategies exist: multiple daily injections (MDI) and continuous subcutaneous insulin infusion via pump.

Multiple Daily Injections (MDI)

MDI typically combines a long-acting basal insulin (glargine, detemir, or degludec) with rapid-acting bolus insulin (lispro, aspart, or glulisine) timed to meals. The DAFNE (Dose Adjustment For Normal Eating) program, developed in Germany and widely adopted in the UK, trains people to count dietary carbohydrates and self-adjust bolus doses accordingly. A 2002 randomized controlled trial published in the BMJ found DAFNE improved HbA1c by 1% while improving quality of life — a rare combination.

Insulin Pumps

Insulin pumps deliver rapid-acting insulin continuously through a subcutaneous cannula, eliminating the need for long-acting basal injections. Programmable basal rates allow fine adjustment for the dawn phenomenon (early-morning glucose rise driven by cortisol and growth hormone). Pumps carry risk of diabetic ketoacidosis if the cannula occludes, since no depot of long-acting insulin exists as a safety net.

Continuous Glucose Monitoring and Closed-Loop Systems

Continuous glucose monitoring (CGM) measures interstitial glucose every 1–5 minutes via an electrochemical sensor placed under the skin. The Dexcom G7 and Abbott FreeStyle Libre 3 now offer factory-calibrated accuracy within 9–10% mean absolute relative difference (MARD). CGM adoption transformed T1D management: the DIAMOND trial (2017) showed CGM users on MDI reduced HbA1c by 1.0 percentage point compared to 0.4% in the finger-stick group.

Closed-loop systems — called the "artificial pancreas" — pair a CGM with an insulin pump controlled by an algorithm that automatically adjusts insulin delivery in real time. The iLet (Beta Bionics), Control-IQ (Tandem), and MiniMed 780G (Medtronic) systems are FDA-cleared. The IDCL pivotal trial (2019) showed Control-IQ users spent 71% of time in range (70–180 mg/dL) versus 59% with sensor-augmented pump therapy alone. Bihormonal systems that also deliver glucagon to prevent hypoglycemia remain under investigation.

The DCCT Trial: Evidence Foundation

The Diabetes Control and Complications Trial (DCCT), conducted from 1983 to 1993 across 29 US and Canadian centers with 1,441 participants, remains the cornerstone evidence base for intensive T1D management. Participants randomized to intensive glycemic control (HbA1c target ~7%) had:

• 76% reduction in retinopathy development
• 50% reduction in nephropathy incidence
• 60% reduction in neuropathy
• 35% reduction in cardiovascular events (shown in the EDIC follow-up study)

The trial's follow-up cohort, EDIC, demonstrated that early intensive control confers "metabolic memory" — lower complication rates persisting decades after HbA1c levels equalized between groups. This finding drove international adoption of tight glycemic targets.

Immune Therapy: Delaying Onset

T1D progresses through identifiable stages. Stage 1: autoantibodies present (against GAD65, IA-2, ZnT8, or insulin) but normoglycemia. Stage 2: dysglycemia without symptoms. Stage 3: clinical diagnosis. Teplizumab (Tzield), an anti-CD3 monoclonal antibody approved by the FDA in November 2022, delays progression from Stage 2 to Stage 3 by a median of 25 months in clinical trials (the TN-10 study, published in NEJM). It is the first disease-modifying therapy for any form of diabetes. Broader beta-cell preservation strategies under study include low-dose IL-2, anti-thymocyte globulin, and regulatory T-cell infusion.

Living With Lifelong Management

T1D demands continuous decision-making. Every meal, every exercise session, every illness shifts insulin requirements. Sick-day rules — often maintaining basal insulin while holding carbohydrates — prevent DKA during illness. Exercise creates variable effects: aerobic activity typically lowers glucose; high-intensity anaerobic activity can raise it via catecholamine release. Hybrid closed-loop systems reduce this burden but do not eliminate the cognitive load. Peer support organizations such as JDRF and Beyond Type 1 provide community infrastructure that clinical systems often cannot.

This article is for informational purposes only. Consult a qualified healthcare professional.